2023
Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study
De Nigris E, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, Huntington S. Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study. Blood 2023, 142: 6523. DOI: 10.1182/blood-2023-178660.Peer-Reviewed Original ResearchB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsProportion of patientsCLL/SLLSmall lymphocytic lymphomaTyrosine kinase inhibitorsLymphocytic lymphomaNew agentsChronic lymphocytic leukemia/small lymphocytic lymphomaMedian age 73 yearsOptum Clinformatics DataMart databaseClinformatics DataMart databaseEnd of eligibilityObservation periodThird of patientsAge 73 yearsClaims-based algorithmChronic lymphocytic leukemiaTreatment classesReal-world studyNovel Bruton's tyrosine kinase inhibitorEligible patientsIndex dateAdult patientsTargeted agents
2022
Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)
Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525). Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.Peer-Reviewed Original ResearchHospice servicesBlood cancersHospice useHematologic malignanciesUtility scoresAdvanced hematologic malignanciesBlood cancer patientsCaregiver focus groupsAdult patientsBlood transfusionMedian ageCancer CenterCancer patientsAcute leukemiaHospice modelValue patientsMedical appointmentsCancer placesPatientsRespite careWeb-based surveyTransfusionCancerCognitive debriefingMalignancySingle-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood 2022, 139: 413-423. PMID: 34570876, PMCID: PMC8777199, DOI: 10.1182/blood.2021012888.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaDouble-hit lymphomaCNS relapse rateCNS relapseRelapse rateCNS prophylaxisCNS-International Prognostic IndexSystemic high-dose methotrexateAggressive non-Hodgkin lymphomaLarge B-cell lymphomaCNS-IPI scoreHigh-dose methotrexateUS academic centersHigh-risk subgroupsNon-Hodgkin lymphomaRoute of administrationB-cell lymphomaSignificant differencesReal-world outcomesCNS-IPIEvaluable patientsFrontline therapyTesticular involvementAdult patientsProphylaxis strategies
2021
Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies
Odejide O, Huntington S, Kuczmarski T, Shi E, Tulsky J, Abel G. Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies. Blood 2021, 138: 4026. DOI: 10.1182/blood-2021-153361.Peer-Reviewed Original ResearchHealthcare teamPrognostic discussionsHematologic oncologistsBlood cancersUnivariable analysisLife expectancyHematologic malignanciesAdvanced hematologic malignanciesHalf of patientsCohort of patientsLarge cancer centerPerceptions of prognosisBlood cancer patientsAccurate prognostic understandingEnd of lifeAdult patientsCommon diagnosisMedian timeOutpatient visitsCancer CenterCancer patientsPrognostic understandingAcute leukemiaPatients' perceptionsOwn life expectancyOverall survival based on oncologist density in the United States: A retrospective cohort study
Malleshappa S, Giri S, Patel S, Mehta T, Appleman L, Huntington SF, Passero V, Parikh RA, Mehta KD. Overall survival based on oncologist density in the United States: A retrospective cohort study. PLOS ONE 2021, 16: e0250894. PMID: 33979399, PMCID: PMC8115849, DOI: 10.1371/journal.pone.0250894.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyHPSA designationOverall survivalCohort studyMedian survivalPrimary careHealth professional shortage area (HPSA) designationsCare servicesShortage Area DesignationEnd Results (SEER) databaseKaplan-Meier methodMetastatic solid cancersMetastatic solid tumorsAmerican Medical Association MasterfileLog-rank testPrimary care servicesAreas of needPatients' median survivalHealth service availabilityHealth care servicesNumber of oncologistsAdult patientsInferior survivalSurveillance EpidemiologyResults database
2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.Peer-Reviewed Original ResearchConceptsIntensive induction chemotherapyAcute myeloid leukemiaHospital deathInduction chemotherapyAdult patientsMultivariable logistic regression modelLow hospital volumePremier Healthcare DatabasePredictors of deathHealthcare resource utilizationIntensive care unitPatterns of careStandard of careLogistic regression modelsFit patientsRemission inductionFirst hospitalizationHospital volumeInpatient deathInpatient mortalityOlder patientsSupportive careMedian ageAML patientsCare unit
2017
Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States
Giri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. Blood 2017, 130: 675. DOI: 10.1182/blood.v130.suppl_1.675.675.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraHospital volumeInpatient mortality rateNationwide Inpatient SampleInpatient mortalityThrombocytopenic purpuraPotential confoundersMortality rateOverall inpatient mortality rateInitiation of plasmapheresisUnique hospital identifiersHigher inpatient mortalityRetrospective cohort studyHigh-volume hospitalsAdjusted odds ratioLogistic regression analysisHierarchical logistic regression analysisTest of trendUnique hospitalizationsHospital mortalityInpatient outcomesHospital courseTotal hospitalizationsVolume hospitalsAdult patients